{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-060726","form_type":"8-K","ticker":"MGTX","cik":"0001735438","company_name":"MeiraGTx Holdings plc","filed_at":"2026-05-14T12:06:12+00:00","discovered_at":"2026-05-14T12:10:00.551540+00:00","generated_at":"2026-05-14T12:18:20.221738+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"MeiraGTx Q1 net loss $46.3M; reacquires bota-vec from J&J; raises $100M","bullets":["Net loss attributable to ordinary shareholders was $46.3M ($0.57 per share) for Q1 2026, vs $40.0M ($0.51) in Q1 2025.","Cash and cash equivalents were $71.5M at March 31, 2026; subsequent $100M equity offering and $25M upfront payment to J&J for bota-vec.","Received FDA Breakthrough Therapy Designation for AAV2-hAQP1 for radiation-induced xerostomia; positive 3-year data from Phase 1 AQUAx study.","Appointed Penny Fleck as Chief Development Officer; Stuart Naylor as Chief Scientific Officer, Ophthalmology.","Reacquired full rights to bota-vec for XLRP from J&J with $25M upfront plus milestones and mid-teens royalties."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-060726","json":"https://secwatch.observer/filing/0001104659-26-060726.json","markdown":"https://secwatch.observer/filing/0001104659-26-060726.md","text":"https://secwatch.observer/filing/0001104659-26-060726.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1735438/000110465926060726/0001104659-26-060726-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1735438/000110465926060726/mgtx-20260514x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T12:18:20.221738+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}